Journal article
A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer
F Day, A Muranyi, S Singh, K Shanmugam, D Williams, D Byrne, K Pham, M Palmieri, J Tie, T Grogan, P Gibbs, O Sieber, P Waring, J Desai
Targeted Oncology | Published : 2015
Abstract
The B-type Raf kinase (BRAF) V600E mutation is a well-established biomarker for poor prognosis in metastatic colorectal cancer (mCRC) and is a highly attractive drug target. A barrier to the development of new therapies targeting BRAF V600E in mCRC is the low prevalence of mutations (approximately 10 %) and the current need for access to sequencing-based technologies which are not routinely available outside of large cancer centres. Availability of a standardised immunohistochemistry (IHC) test, more suited to routine pathology practice, would provide much broader access to patient identification. We sought to evaluate the accuracy and clinical utility of a recently developed BRAF V600E IHC ..
View full abstractGrants
Funding Acknowledgements
This study was supported by the Victorian Government through the Operational Infrastructure Support Program, the Victorian Cancer Agency and the Australian Government through the National Health Medical Research Council and Ventana Medical Systems, Inc. J.D. is supported by the Victorian Government through a Victorian Cancer Agency Clinical Researcher Fellowship. F.D. is supported by the Cancer Council Victoria through a Postgraduate Cancer Research Scholarship.